Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Obesity · 2025-03 · 33 (3) · 452-462
DOI: 10.1002/oby.24222 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, online erschienen am 13.02.2025. Verfasst von Robert F Kushner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Cardiovascular Diseases, Obesity, Overweight. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Novo Nordisk A/S.
Abstract (Originalsprache)
Objective
The objective of this study was to assess safety of once‐weekly subcutaneous semaglutide 2.4 mg versus placebo, beyond reduction in major adverse cardiovascular events, in patients with established cardiovascular disease and overweight or obesity.
Methods
Safety data focused on serious adverse events (SAEs), all adverse events (AEs) leading to permanent treatment discontinuation irrespective of seriousness, and prespecified AEs of special interest irrespective of seriousness. Tests of treatment differences were determined by two‐sided p values.
Results
The proportion of patients with SAEs was lower with semaglutide versus placebo (33.4% vs. 36.4%; p < 0.001), primarily driven by cardiac disorders (11.5% vs. 13.5%; p < 0.001). The proportion of patients with AEs leading to discontinuation was higher with semaglutide versus placebo (16.6% vs. 8.2%; p < 0.001), a difference driven by gastrointestinal disorders (10.0% vs. 2.0%); however, proportions due to SAEs leading to discontinuation were similar (3.6% vs. 4.1%). Suicide/self‐injury SAEs were low and balanced between groups (0.11% in both groups). Gallbladder‐related disorders were more frequent with semaglutide versus placebo (2.8% vs. 2.3%; p = 0.04), mainly driven by cholelithiasis (1.4% vs. 1.1%), whereas proportions of cholecystitis were similar between groups (0.6% vs. 0.6%).
Conclusions
The long‐term safety profile observed in the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) study is consistent with previously reported semaglutide studies. No new safety concerns were identified for once‐weekly semaglutide 2.4 mg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
- Institute of Cardiovascular Science, University College London, London, UK.
- First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Obesity Unit, Department of Endocrinology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
- Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
ORCID-Profile: Robert F Kushner, Bartolome Burguera, Ildiko Lingvay
Förderung
- NIDDK NIH HHS
- Novo Nordisk A/S
Zitieren
APA
Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C. C., Craciun, A. E., Pall, D., Hramiak, I., Hjelmesæth, J., Harder-Lauridsen, N. M., Weimers, P., Jeppesen, O. K., Kallenbach, K., Lincoff, A. M., & Lingvay, I. (2025). Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity, 33(3), 452-462. https://doi.org/10.1002/oby.24222
Vancouver
Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity. 2025;33(3):452-462. doi:10.1002/oby.24222
BibTeX
@article{Kushner2025,
author = {Kushner, Robert F and Ryan, Donna H and Deanfield, John and Kokkinos, Alexander and Cercato, Cintia and Wilding, John and Burguera, Bartolome and Wu, Chau-Chung and Craciun, Anca-Elena and Pall, Denes and Hramiak, Irene and Hjelmesæth, Jøran and Harder-Lauridsen, Nina M and Weimers, Petra and Jeppesen, Ole Kleist and Kallenbach, Klaus and Lincoff, A Michael and Lingvay, Ildiko},
title = {Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial},
journal = {Obesity},
year = {2025},
volume = {33},
number = {3},
pages = {452--462},
doi = {10.1002/oby.24222}
}
EUVIMED